Graft Versus Host Disease (GVHD) Treatment Market Report

Global and Region Graft Versus Host Disease (GVHD) Treatment Market Demand & Opportunity Outlook 2022-2028

  • POSTDATE：Jul 29, 2022
  • PAGES：165
  • REPORT CODE：GMM885690
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The report details the trend, potential and market size of Graft Versus Host Disease (GVHD) Treatment market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.

    The first part (Chapter1-7) mainly covers the qualitative analysis of Graft Versus Host Disease (GVHD) Treatmentmarket, defines the market attractiveness level of Graft Versus Host Disease (GVHD) Treatment market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.

    The second part (Chapter8-12), based on the segmentation of Graft Versus Host Disease (GVHD) Treatment industry, describes the types of Graft Versus Host Disease (GVHD) Treatment market, the applications of major players and the market size, and deeply analyzes the current situation of the global Graft Versus Host Disease (GVHD) Treatment market and the development prospects and opportunities of Graft Versus Host Disease (GVHD) Treatment industry.

    The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.

    As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Graft Versus Host Disease (GVHD) Treatment market in Chapter 13.

    By Player:

    • Shire

    • Glenmark

    • Bristol-Myers Squibb

    • Astellas Pharma

    • Sanofi

    • Caladrius

    • Osiris therapeutics

    • Каdmоn Ноldingѕ

    • Allergan

    • GlaxoSmithKline

    • Anterogrn

    • Eli Lilly

    • Аthеrѕyѕ

    • AbbVie

    • Abbott

    By Type:

    • Monoclonal Antibodies

    • MTOR Inhibitors

    • Tyrosine Kinase Inhibitors

    • Thalidomide

    • Etanercept

    By End-User:

    • Acute Graft Versus Host Disease (AGVHD)

    • Chronic Graft Versus Host Disease (CGVHD)

    By Geography:

    • United States

    • Europe

    • China

    • Japan

    • India

    • South Korea

  • TABLE OF CONTENT

    1 Introduction

    • 1.1 Market Definition

    • 1.2 Market Segment Analysis

    • 1.3 Market Size 2022

    • 1.4 Graft Versus Host Disease (GVHD) Treatment Market Outlook: Forecast for 2022 - 2028

    • 1.5 Pricing Analysis

    2 Executive Summary

    3 Graft Versus Host Disease (GVHD) Treatment Market Lineage Outlook

    • 3.1 Parent Market Outlook

    • 3.2 Related/Ancillary Market Outlook

    • 3.3 Penetration & Growth Prospect Mapping, 2022

    4 Market Analysis Tools: Porter's Five Forces

    • 4.1 Supplier Power

    • 4.2 Buyer Power

    • 4.3 Substitution Threat

    • 4.4 Threat of New Entrants

    • 4.5 Competitive Rivalry

    5 Graft Versus Host Disease (GVHD) Treatment Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)

    • 5.1 Political/Legal Landscape

    • 5.2 Economic Landscape

    • 5.3 Social Landscape

    • 5.4 Technology Landscape

    6 Graft Versus Host Disease (GVHD) Treatment Market - Value Chain Analysis

    • 6.1 Industry's Value Chain Analysis

    • 6.2 Product Life Cycle

    • 6.3 User Perspective Analysis

    7 Region and Country-wise Graft Versus Host Disease (GVHD) Treatment Market Analysis and Outlook to 2022

    • 7.1 Global Graft Versus Host Disease (GVHD) Treatment Consumption (2017-2022)

    • 7.2 United States Graft Versus Host Disease (GVHD) Treatment Consumption (2017-2022)

    • 7.3 Europe Graft Versus Host Disease (GVHD) Treatment Consumption (2017-2022)

    • 7.4 China Graft Versus Host Disease (GVHD) Treatment Consumption (2017-2022)

    • 7.5 Japan Graft Versus Host Disease (GVHD) Treatment Consumption (2017-2022)

    • 7.6 India Graft Versus Host Disease (GVHD) Treatment Consumption (2017-2022)

    • 7.7 South Korea Graft Versus Host Disease (GVHD) Treatment Consumption (2017-2022)

    8 Region and Country-wise Graft Versus Host Disease (GVHD) Treatment Market Analysis and Outlook to 2028

    • 8.1 Global Graft Versus Host Disease (GVHD) Treatment Consumption Forecast (2022-2028)

    • 8.2 United States Graft Versus Host Disease (GVHD) Treatment Consumption Forecast (2022-2028)

    • 8.3 Europe Graft Versus Host Disease (GVHD) Treatment Consumption Forecast (2022-2028)

    • 8.4 China Graft Versus Host Disease (GVHD) Treatment Consumption Forecast (2022-2028)

    • 8.5 Japan Graft Versus Host Disease (GVHD) Treatment Consumption Forecast (2022-2028)

    • 8.6 India Graft Versus Host Disease (GVHD) Treatment Consumption Forecast (2022-2028)

    • 8.7 South Korea Graft Versus Host Disease (GVHD) Treatment Consumption Forecast (2022-2028)

    9 Global Graft Versus Host Disease (GVHD) Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Graft Versus Host Disease (GVHD) Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global MTOR Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Tyrosine Kinase Inhibitors Consumption and Growth Rate (2017-2022)

      • 9.1.4 Global Thalidomide Consumption and Growth Rate (2017-2022)

      • 9.1.5 Global Etanercept Consumption and Growth Rate (2017-2022)

    • 9.2 Global Graft Versus Host Disease (GVHD) Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Acute Graft Versus Host Disease (AGVHD) Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Chronic Graft Versus Host Disease (CGVHD) Consumption and Growth Rate (2017-2022)

    10 Global Graft Versus Host Disease (GVHD) Treatment Market Outlook by Types and Applications to 2028

    • 10.1 Global Graft Versus Host Disease (GVHD) Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 10.1.1 Global Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.2 Global MTOR Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.3 Global Tyrosine Kinase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.4 Global Thalidomide Consumption Forecast and Growth Rate (2022-2028)

      • 10.1.5 Global Etanercept Consumption Forecast and Growth Rate (2022-2028)

    • 10.2 Global Graft Versus Host Disease (GVHD) Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 10.2.1 Global Acute Graft Versus Host Disease (AGVHD) Consumption Forecast and Growth Rate (2022-2028)

      • 10.2.2 Global Chronic Graft Versus Host Disease (CGVHD) Consumption Forecast and Growth Rate (2022-2028)

    11 Global Graft Versus Host Disease (GVHD) Treatment Import and Export Analysis (Top 5 Countries)

    • 11.1 Global Graft Versus Host Disease (GVHD) Treatment Import by Region (Top 5 Countries) (2017-2028)

    • 11.2 Global Graft Versus Host Disease (GVHD) Treatment Export by Region (Top 5 Countries) (2017-2028)

    12 Coronavirus Disease (COVID-19) Impact

    • 12.1 Industry Impact Analysis

    • 12.2 Graft Versus Host Disease (GVHD) Treatment Market Outlook to 2028 - COVID-19 Affected Forecasts

    13 Competition Matrix

    • 13.1 Target Markets

    • 13.2 Comprehensive Analysis of Products in Competitive Markets

    14 Global Graft Versus Host Disease (GVHD) Treatment Market Competitive Analysis

    • 14.1 Shire

      • 14.1.1 Shire Company Details

      • 14.1.2 Shire Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.1.3 Shire Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.2 Glenmark

      • 14.2.1 Glenmark Company Details

      • 14.2.2 Glenmark Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.2.3 Glenmark Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.3 Bristol-Myers Squibb

      • 14.3.1 Bristol-Myers Squibb Company Details

      • 14.3.2 Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.3.3 Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.4 Astellas Pharma

      • 14.4.1 Astellas Pharma Company Details

      • 14.4.2 Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.4.3 Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.5 Sanofi

      • 14.5.1 Sanofi Company Details

      • 14.5.2 Sanofi Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.5.3 Sanofi Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.6 Caladrius

      • 14.6.1 Caladrius Company Details

      • 14.6.2 Caladrius Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.6.3 Caladrius Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.7 Osiris therapeutics

      • 14.7.1 Osiris therapeutics Company Details

      • 14.7.2 Osiris therapeutics Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.7.3 Osiris therapeutics Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.8 Каdmоn Ноldingѕ

      • 14.8.1 Каdmоn Ноldingѕ Company Details

      • 14.8.2 Каdmоn Ноldingѕ Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.8.3 Каdmоn Ноldingѕ Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.9 Allergan

      • 14.9.1 Allergan Company Details

      • 14.9.2 Allergan Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.9.3 Allergan Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.10 GlaxoSmithKline

      • 14.10.1 GlaxoSmithKline Company Details

      • 14.10.2 GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.10.3 GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.11 Anterogrn

      • 14.11.1 Anterogrn Company Details

      • 14.11.2 Anterogrn Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.11.3 Anterogrn Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.12 Eli Lilly

      • 14.12.1 Eli Lilly Company Details

      • 14.12.2 Eli Lilly Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.12.3 Eli Lilly Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.13 Аthеrѕyѕ

      • 14.13.1 Аthеrѕyѕ Company Details

      • 14.13.2 Аthеrѕyѕ Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.13.3 Аthеrѕyѕ Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.14 AbbVie

      • 14.14.1 AbbVie Company Details

      • 14.14.2 AbbVie Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.14.3 AbbVie Graft Versus Host Disease (GVHD) Treatment Product and Service

    • 14.15 Abbott

      • 14.15.1 Abbott Company Details

      • 14.15.2 Abbott Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 14.15.3 Abbott Graft Versus Host Disease (GVHD) Treatment Product and Service

    15 Appendix


    TABLE OF CHARTS

    • Table Definition of Graft Versus Host Disease (GVHD) Treatment

    • Figure Graft Versus Host Disease (GVHD) Treatment Picture

    • Table Global Graft Versus Host Disease (GVHD) Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Graft Versus Host Disease (GVHD) Treatment Market Size and Forecast 2022 - 2028 (USD million)

    • Figure Global Graft Versus Host Disease (GVHD) Treatment Market: Year-over-year Growth 2022 - 2028 (%)

    • Table Parent Market Analysis

    • Figure Parent Market Price

    • Table Related/Ancillary Market Outlook Analysis

    • Table Supplier Power Analysis

    • Table Buyer Power Analysis

    • Table Substitution Threat Analysis

    • Table Threat of New Entrants Analysis

    • Table Competitive Rivalry Analysis

    • Figure Global Graft Versus Host Disease (GVHD) Treatment Consumption by Country (2017-2022)

    • Figure United States Graft Versus Host Disease (GVHD) Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Graft Versus Host Disease (GVHD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure China Graft Versus Host Disease (GVHD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Graft Versus Host Disease (GVHD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Graft Versus Host Disease (GVHD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Graft Versus Host Disease (GVHD) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Global Graft Versus Host Disease (GVHD) Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Graft Versus Host Disease (GVHD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Graft Versus Host Disease (GVHD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure China Graft Versus Host Disease (GVHD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Graft Versus Host Disease (GVHD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Graft Versus Host Disease (GVHD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Graft Versus Host Disease (GVHD) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Monoclonal Antibodies Consumption and Growth Rate (2017-2022)

    • Figure Global MTOR Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Tyrosine Kinase Inhibitors Consumption and Growth Rate (2017-2022)

    • Figure Global Thalidomide Consumption and Growth Rate (2017-2022)

    • Figure Global Etanercept Consumption and Growth Rate (2017-2022)

    • Figure Global Acute Graft Versus Host Disease (AGVHD) Consumption and Growth Rate (2017-2022)

    • Figure Global Chronic Graft Versus Host Disease (CGVHD) Consumption and Growth Rate (2017-2022)

    • Figure Global Monoclonal Antibodies Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global MTOR Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Tyrosine Kinase Inhibitors Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Thalidomide Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Etanercept Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Acute Graft Versus Host Disease (AGVHD) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Chronic Graft Versus Host Disease (CGVHD) Consumption Forecast and Growth Rate (2022-2028)

    • Table Global Graft Versus Host Disease (GVHD) Treatment Import by Region (Top 5 Countries) (2017-2028)

    • Table Global Graft Versus Host Disease (GVHD) Treatment Export by Region (Top 5 Countries) (2017-2028)

    • Table Shire (Foundation Year, Company Profile and etc.)

    • Table Shire Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Shire Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table Glenmark (Foundation Year, Company Profile and etc.)

    • Table Glenmark Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Glenmark Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table Bristol-Myers Squibb (Foundation Year, Company Profile and etc.)

    • Table Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Bristol-Myers Squibb Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table Astellas Pharma (Foundation Year, Company Profile and etc.)

    • Table Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Astellas Pharma Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table Sanofi (Foundation Year, Company Profile and etc.)

    • Table Sanofi Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table Caladrius (Foundation Year, Company Profile and etc.)

    • Table Caladrius Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Caladrius Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table Osiris therapeutics (Foundation Year, Company Profile and etc.)

    • Table Osiris therapeutics Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Osiris therapeutics Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table Каdmоn Ноldingѕ (Foundation Year, Company Profile and etc.)

    • Table Каdmоn Ноldingѕ Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Каdmоn Ноldingѕ Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table Allergan (Foundation Year, Company Profile and etc.)

    • Table Allergan Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Allergan Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)

    • Table GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table GlaxoSmithKline Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table Anterogrn (Foundation Year, Company Profile and etc.)

    • Table Anterogrn Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Anterogrn Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table Eli Lilly (Foundation Year, Company Profile and etc.)

    • Table Eli Lilly Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Eli Lilly Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table Аthеrѕyѕ (Foundation Year, Company Profile and etc.)

    • Table Аthеrѕyѕ Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Аthеrѕyѕ Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table AbbVie (Foundation Year, Company Profile and etc.)

    • Table AbbVie Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table AbbVie Graft Versus Host Disease (GVHD) Treatment Product and Service

    • Table Abbott (Foundation Year, Company Profile and etc.)

    • Table Abbott Graft Versus Host Disease (GVHD) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Abbott Graft Versus Host Disease (GVHD) Treatment Product and Service


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US